

Darrell J Yamashiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2993607/publications.pdf>

Version: 2024-02-01

86
papers

4,343
citations

126907

33
h-index

106344

65
g-index

88
all docs

88
docs citations

88
times ranked

5129
citing authors

#	ARTICLE	IF	CITATIONS
1	Segregation of transferrin to a mildly acidic (pH 6.5) para-golgi compartment in the recycling pathway. <i>Cell</i> , 1984, 37, 789-800.	28.9	566
2	Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11399-11404.	7.1	305
3	Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 399-405.	1.6	240
4	Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7785-7790.	7.1	234
5	Biology and Genetics of Human Neuroblastomas. <i>The American Journal of Pediatric Hematology/Oncology</i> , 1997, 19, 93-101.	1.3	205
6	VEGF blocking therapy in the treatment of cancer. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 263-276.	3.1	159
7	HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma. <i>Nature Medicine</i> , 2016, 22, 1180-1186.	30.7	158
8	A Notch1 Ectodomain Construct Inhibits Endothelial Notch Signaling, Tumor Growth, and Angiogenesis. <i>Cancer Research</i> , 2008, 68, 4727-4735.	0.9	147
9	Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. <i>Genome Medicine</i> , 2016, 8, 133.	8.2	147
10	Identification of a patient with Bernard-Soulier syndrome and a deletion in the DiGeorge/Velo-cardio-facial chromosomal region in 22q11.2. <i>Human Molecular Genetics</i> , 1995, 4, 763-766.	2.9	144
11	Acidification of endocytic compartments and the intracellular pathways of ligands and receptors. <i>Journal of Cellular Biochemistry</i> , 1984, 26, 231-246.	2.6	125
12	Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. <i>Journal of Pediatric Surgery</i> , 2000, 35, 30-33.	1.6	115
13	Polyplex-microbubble hybrids for ultrasound-guided plasmid DNA delivery to solid tumors. <i>Journal of Controlled Release</i> , 2012, 157, 224-234.	9.9	112
14	Endosome Acidification and the Pathways of Receptor-Mediated Endocytosis. <i>Advances in Experimental Medicine and Biology</i> , 1987, 225, 189-198.	1.6	99
15	Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis. <i>Molecular Cancer Research</i> , 2004, 2, 36-42.	3.4	90
16	Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). <i>Genomics</i> , 1995, 25, 538-546.	2.9	88
17	Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. <i>Drug Resistance Updates</i> , 2004, 7, 289-300.	14.4	82
18	Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. <i>Journal of Pediatric Surgery</i> , 2001, 36, 357-361.	1.6	65

#	ARTICLE	IF	CITATIONS
19	PDE-constrained multispectral imaging of tissue chromophores with the equation of radiative transfer. <i>Biomedical Optics Express</i> , 2010, 1, 812.	2.9	65
20	Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms' tumorigenesis and methylation hyper-dependence of H19 imprinting. <i>Human Molecular Genetics</i> , 1999, 8, 1337-1352.	2.9	64
21	Genomic Profiling Maps Loss of Heterozygosity and Defines the Timing and Stage Dependence of Epigenetic and Genetic Events in Wilms' Tumors. <i>Molecular Cancer Research</i> , 2005, 3, 493-502.	3.4	62
22	Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms tumor. <i>Journal of Pediatric Surgery</i> , 2001, 36, 1177-1181.	1.6	61
23	Contrast Ultrasound Imaging for Identification of Early Responder Tumor Models to Anti-Angiogenic Therapy. <i>Ultrasound in Medicine and Biology</i> , 2012, 38, 1019-1029.	1.5	53
24	Regulation of endocytic processes by pH. <i>Trends in Pharmacological Sciences</i> , 1988, 9, 190-193.	8.7	52
25	Biomolecular markers and involution of hemangiomas. <i>Journal of Pediatric Surgery</i> , 2004, 39, 400-404.	1.6	49
26	Notch Suppresses Angiogenesis and Progression of Hepatic Metastases. <i>Cancer Research</i> , 2015, 75, 1592-1602.	0.9	45
27	Suppression of primary tumor growth in a mouse model of human neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2000, 35, 977-981.	1.6	41
28	Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. <i>Journal of Pediatric Surgery</i> , 2002, 37, 518-522.	1.6	41
29	Chromosome arm 16q in Wilms tumors: Unbalanced chromosomal translocations, loss of heterozygosity, and assessment of theCTCF gene. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 156-163.	2.8	40
30	The association between neuroblastoma and opsoclonus-myooclonus syndrome: a historical review. <i>Pediatric Radiology</i> , 2009, 39, 723-726.	2.0	40
31	Kinetics of ?2-macroglobulin endocytosis and degradation in mutant and wild-type Chinese hamster ovary cells. <i>Journal of Cellular Physiology</i> , 1989, 139, 377-382.	4.1	39
32	All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. <i>Journal of Pediatric Surgery</i> , 2001, 36, 287-290.	1.6	37
33	Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. <i>Journal of Pediatric Surgery</i> , 2001, 36, 1781-1784.	1.6	35
34	Anti-VEGF antibody in experimental hepatoblastoma: Suppression of tumor growth and altered angiogenesis. <i>Journal of Pediatric Surgery</i> , 2003, 38, 308-314.	1.6	32
35	Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis. <i>Vascular Cell</i> , 2013, 5, 17.	0.2	31
36	High-Dose, Single-Fraction Irradiation Rapidly Reduces Tumor Vasculature and Perfusion in a Xenograft Model of Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1173-1180.	0.8	28

#	ARTICLE	IF	CITATIONS
37	Structure-Activity Relationships of Somatostatin Analogs in the Rabbit Ileum and the Rat Colon. <i>Journal of Clinical Investigation</i> , 1983, 71, 840-849.	8.2	28
38	Topotecan is anti-angiogenic in experimental hepatoblastoma. <i>Journal of Pediatric Surgery</i> , 2002, 37, 857-861.	1.6	26
39	Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms's tumor. <i>Journal of Pediatric Surgery</i> , 2003, 38, 1569-1573.	1.6	25
40	Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. <i>Pediatric Blood and Cancer</i> , 2009, 52, 669-671.	1.5	25
41	Clinical Development of VEGF Signaling Pathway Inhibitors in Childhood Solid Tumors. <i>Oncologist</i> , 2011, 16, 1614-1625.	3.7	23
42	Monitoring early tumor response to drug therapy with diffuse optical tomography. <i>Journal of Biomedical Optics</i> , 2012, 17, 016014.	2.6	23
43	A screen for inducers of p21waf1/cip1 identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties. <i>Neurobiology of Disease</i> , 2013, 49, 13-21.	4.4	23
44	Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma. <i>Oncogene</i> , 2018, 37, 5451-5465.	5.9	22
45	TNP-470 promotes initial vascular sprouting in xenograft tumors. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 335-43.	4.1	22
46	ACIDIFICATION OF ENDOCYTIC VESICLES AND THE INTRACELLULAR PATHWAYS OF LIGANDS AND RECEPTORS. <i>Annals of the New York Academy of Sciences</i> , 1983, 421, 424-433.	3.8	21
47	P53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease. <i>Journal of Pediatric Surgery</i> , 2002, 37, 523-527.	1.6	19
48	Correlation of tumor-associated macrophages and clinicopathological factors in Wilms tumor. <i>Vascular Cell</i> , 2013, 5, 5.	0.2	16
49	Malignant Rhabdoid Tumor, an Aggressive Tumor Often Misclassified as Small Cell Variant of Hepatoblastoma. <i>Cancers</i> , 2019, 11, 1992.	3.7	16
50	Vascular characterization of clear cell sarcoma of the kidney in a child: a case report and review. <i>Journal of Pediatric Surgery</i> , 2009, 44, 2031-2036.	1.6	15
51	A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. <i>Genome Medicine</i> , 2016, 8, 116.	8.2	15
52	Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. <i>International Journal of Oncology</i> , 2004, 25, 549.	3.3	14
53	Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. <i>International Journal of Oncology</i> , 2009, 34, 401-7.	3.3	14
54	Stable liver graft post anti-CPD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma. <i>Pediatric Transplantation</i> , 2022, 26, e14209.	1.0	11

#	ARTICLE	IF	CITATIONS
55	Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor. <i>Vascular Cell</i> , 2011, 3, 22.	0.2	10
56	High-Dose Radiation Increases Notch1 in Tumor Vasculature. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 857-866.	0.8	10
57	Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. <i>International Journal of Oncology</i> , 2003, 23, 1651.	3.3	9
58	A Challenging Case of Hepatoblastoma Concomitant with Autosomal Recessive Polycystic Kidney Disease and Caroli Syndrome—Review of the Literature. <i>Frontiers in Pediatrics</i> , 2017, 5, 114.	1.9	8
59	Disseminated trichosporonosis with atypical histologic findings in a patient with acute lymphocytic leukemia. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 159-161.	1.3	8
60	Resistance of a VEGF-producing tumor to anti-VEGF antibody: Unimpeded growth of human rhabdoid tumor xenografts. <i>Journal of Pediatric Surgery</i> , 2002, 37, 528-532.	1.6	7
61	Biology and Genetics of Human Neuroblastomas. <i>Journal of Pediatric Hematology/Oncology</i> , 1997, 19, 93-101.	0.6	7
62	Erythema nodosum arising during everolimus therapy for tuberous sclerosis complex. <i>Pediatric Dermatology</i> , 2018, 35, e235-e236.	0.9	6
63	Polyplex-microbubbles for ultrasound-mediated gene therapy. <i>Proceedings of Meetings on Acoustics</i> , 2013, , .	0.3	4
64	Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. <i>Oncology Reports</i> , 0, , .	2.6	4
65	Monitoring of anti-angiogenic drug response with dynamic fluorescence imaging. , 2010, , .		2
66	A Common Symptom of an Uncommon Disease. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, 390-391.	0.6	2
67	INI1 negative hepatoblastoma, a vanishing entity representing malignant rhabdoid tumor. <i>Human Pathology: Case Reports</i> , 2018, 12, 42-47.	0.2	2
68	Dynamic Fluorescence Imaging For The Detection of Vascular Changes in Anti-Angiogenic Drug Therapy. , 2010, , .		2
69	Novel <i>CD63-PRKCB</i> fusion in a case of pigmented epithelioid melanocytoma. <i>Pediatric Dermatology</i> , 2022, 39, 322-323.	0.9	2
70	Transport-theory based multispectral imaging with PDE-constrained optimization. , 2011, , .		1
71	Abstract 1946: Activating transcription factor 5 (ATF5) is highly expressed in Stage 4, MYCN-amplified neuroblastoma. , 2015, , .		1
72	Abstract 702: A novel cell-penetrating ATF5 antagonist peptide CP-d/n-ATF5 exerts in vitro and in vivo anti-tumor effects in a broad spectrum of pediatric cancers. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
73	Early Detection of Tumor Vascular Response to Anti-Angiogenic Drugs with Optical Tomography. , 2010, , .		1
74	VEGF blocking therapy in the treatment of cancer. Expert Opinion on Biological Therapy, 2003, 3, 263-276.	3.1	1
75	Inhibition of notch promotes liver metastasis. Aging, 2015, 7, 603-604.	3.1	1
76	Comparing tumor response to VEGF blockade therapy using high frequency ultrasound imaging with size-selected microbubble contrast agents. , 2010, , .		0
77	Optical tomographic monitoring of vascular responses to anti-angiogenic drugs in preclinical tumor models. , 2011, , .		0
78	Inhibition of host Notch function disrupts hepatic vasculature, and promotes tumor growth. Journal of the American College of Surgeons, 2012, 215, S70-S71.	0.5	0
79	Notch1 Signaling in Neuroblastoma Tumor Vasculature after High-Dose Radiation Therapy. Journal of the American College of Surgeons, 2018, 227, S198.	0.5	0
80	4304 Immune markers in tumor immune microenvironment of neuroblastoma correlate with risk groups. Journal of Clinical and Translational Science, 2020, 4, 136-136.	0.6	0
81	Optical Tomographic Imaging of Tumor Hemodynamics during Anti-VEGF Treatment in Mice. , 2006, , .		0
82	Angiogenesis in Tumour Development and Metastasis. , 2010, , 81-93.		0
83	Abstract 1282: Notch and VEGF regulate tumor endothelial cell survival. , 2010, , .		0
84	Abstract 2325: Increase in neuroblastoma metastasis after dual inhibition of VEGF and Notch. , 2012, , .		0
85	Abstract 2083: TFAP4 inhibits differentiation of MYCN-amplified neuroblastoma. , 2015, , .		0
86	Abstract A27: INI1 negative hepatoblastoma, a vanishing entity representing malignant rhabdoid tumor. , 2016, , .		0